Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
基本信息
- 批准号:10406250
- 负责人:
- 金额:$ 42.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-17 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary
Humoral immunity crucially protects against pathogens but can function as a pathogenic mediator of multiple
autoimmune and alloimmune disease processes, the latter including chronic graft vs. host disease and
antibody-mediated solid organ transplant rejection. Development of antigen-specific antibody responses
requires T cell-dependent B cell activation and the formation of germinal centers (GC), transient lymphoid
structures where somatic hypermutation and affinity maturation events result in the generation of high affinity,
antibody-producing plasma cells (PC) and memory B cells (Bmem). The physiological signals that control GC
formation and GC B cell fates are incompletely characterized. Our preliminary data identify a previously
unappreciated role for decay accelerating factor (DAF or CD55), a cell surface-expressed complement
regulatory protein, in controlling GC reactions and their resultant output, the production of PC and Bmem. Our
data support the hypothesis that optimal GC function requires downregulation of cell surface expressed DAF
on responding B cells, a process that lifts restraint on local, alternative pathway complement activation and
facilitates C3- and C5-convertase formation and production of C3 and C5 cleavage products. This process
promotes C3a/C3aR1 and C5a/C5aR1 ligations on GC B cells, which would in turn transduce signals
controlling GC B cell proliferation, survival, somatic hypermutation, and/or affinity maturation, and as a
consequence, influence differentiation into memory B cells and/or plasma cells. We will test this paradigm-
shifting hypothesis using unique biological reagents and through 3 interactive aims: 1) To determine the effects
of B cell-expressed DAF, C3aR1 and C5aR1 on T cell-dependent humoral immune responses and distinguish
them from the effects of B cell-expressed CD21. 2) To determine the cellular and molecular mechanisms
through which DAF downregulation and enhanced signaling through C3aR1/C5aR1 in B cells drive affinity
maturation. 3) To determine the molecular basis of DAF downregulation on B cells. This comprehensive
analysis performed by a multi-PI team with expertise in complement biology (Heeger) and B cell biology
(Dominguez-Sola) is likely to provide new insight into fundamental mechanisms of GC dynamics and function.
The results have the potential to guide second order studies aimed at exploiting the complement/B cell axis to
either inhibit development of pathogenic B cell responses (e.g. in transplantation or autoimmunity) or augment
B cell response (e.g. in response to vaccines).
项目摘要
体液免疫力至关重要地预防病原体,但可以充当多重病原体的介体
自身免疫性和同种免疫性疾病过程,后者包括慢性移植与宿主疾病和
抗体介导的固体器官移植排斥。抗原特异性抗体反应的发展
需要T细胞依赖性B细胞激活和生发中心(GC)的形成,瞬态淋巴样
体细胞超成熟和亲和力成熟事件导致高亲和力产生的结构,
产生抗体的浆细胞(PC)和记忆B细胞(BMEM)。控制GC的生理信号
形成和GC B细胞命运未完全表征。我们的初步数据确定了先前的
衰减加速因子(DAF或CD55)的未欣赏角色,一种细胞表面表达的补体
调节蛋白在控制GC反应及其产量时,PC和BMEM的产生。我们的
数据支持最佳GC功能需要下调细胞表面表达DAF的假设
在响应B细胞时,该过程可以限制局部替代途径补充激活和
促进C3-和C5-转化酶形成以及C3和C5裂解产品的产生。这个过程
在GC B细胞上促进C3A/C3AR1和C5A/C5AR1绑扎,这又会传输信号
控制GC B细胞增殖,存活,体细胞超成名和/或亲和力成熟,并作为A
结果,影响分化为记忆B细胞和/或浆细胞。我们将测试此范式 -
使用独特的生物试剂转移假设,并通过3个交互式目的:1)确定影响
B细胞表达的DAF,C3AR1和C5AR1在T细胞依赖性体液免疫反应上的
它们来自B细胞表达的CD21的影响。 2)确定细胞和分子机制
通过在B细胞中通过C3AR1/C5AR1通过C3AR1/C5AR1的DAF下调和增强的信号传导驱动亲和力
成熟。 3)确定B细胞上DAF下调的分子基础。这个全面
由具有补体生物学专业知识(HEEGER)和B细胞生物学专业知识的多PI团队进行的分析
(Dominguez-Sola)可能会提供有关GC动力学和功能基本机制的新见解。
结果有可能指导旨在利用补体/B细胞轴的二阶研究
抑制致病性B细胞反应的发展(例如,移植或自身免疫性)或增强
B细胞反应(例如,对疫苗的响应)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
David Dominguez-S...的其他基金
Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
- 批准号:98173229817322
- 财政年份:2019
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Decay Accelerating Factor and B cell Immunity
衰变加速因子和 B 细胞免疫
- 批准号:1062328810623288
- 财政年份:2019
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
- 批准号:1033443510334435
- 财政年份:2018
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Role of FOXO1 mutations in the pathogenesis of B cell non-Hodgkin lymphomas
FOXO1突变在B细胞非霍奇金淋巴瘤发病机制中的作用
- 批准号:1008789510087895
- 财政年份:2018
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
- 批准号:81461778146177
- 财政年份:2010
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
ROLE OF REPLICATION STRESS DURING MYC-DEPENDENT LYMPHOMAGENESIS
复制应激在 MYC 依赖性淋巴细胞生成过程中的作用
- 批准号:79623867962386
- 财政年份:2010
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Role of Replication Stress during Myc-dependent Lymphomagenesis
复制应激在 Myc 依赖性淋巴瘤发生过程中的作用
- 批准号:87851738785173
- 财政年份:2010
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Role of Replication Stress during Myc-dependent Lymphomagenesis
复制应激在 Myc 依赖性淋巴瘤发生过程中的作用
- 批准号:88195188819518
- 财政年份:2010
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
相似国自然基金
基于计算生物学技术小分子农兽药残留物驼源单域抗体虚拟筛选与亲和力成熟 -以内蒙古阿拉善双峰驼为例
- 批准号:32360190
- 批准年份:2023
- 资助金额:34 万元
- 项目类别:地区科学基金项目
基于胞内蛋白亲和力标记策略进行新型抗类风湿性关节炎的选择性OGG1小分子抑制剂的发现
- 批准号:82304698
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于多尺度表征和跨模态语义匹配的药物-靶标结合亲和力预测方法研究
- 批准号:62302456
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
框架核酸多价人工抗体增强靶细胞亲和力用于耐药性肿瘤治疗
- 批准号:32301185
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
抗原非特异性B细胞进入生发中心并实现亲和力成熟的潜力与调控机制
- 批准号:32370941
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Innovative therapeutic strategies to support elimination of river blindness
支持消除河盲症的创新治疗策略
- 批准号:1075412010754120
- 财政年份:2023
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Mapping tumor specific immunopeptidome for antibody-based targeted therapy
绘制肿瘤特异性免疫肽组用于基于抗体的靶向治疗
- 批准号:1060494110604941
- 财政年份:2023
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Disease Modifying Treatment for Hemolytic Disorders
溶血性疾病的疾病修饰治疗
- 批准号:1025475010254750
- 财政年份:2021
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Identification of the mechanism of protection against a B. burgdorferi protein CspZ for the prevention of Lyme disease
鉴定伯氏疏螺旋体蛋白 CspZ 预防莱姆病的机制
- 批准号:1009056210090562
- 财政年份:2020
- 资助金额:$ 42.38万$ 42.38万
- 项目类别:
Structure/Function Studies of LILRs Enabled by a Bacterially-Derived Ligand
由细菌衍生的配体实现的 LILR 的结构/功能研究
- 批准号:1030808910308089
- 财政年份:2020
- 资助金额:$ 42.38万$ 42.38万
- 项目类别: